Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide Lym-X-Sorb™ , work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing.
PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide
Lym-X-Sorb™ in treating patients with recurrent or resistant solid tumors or lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)